Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Diabetologia. 2024 Apr;67(4):758. doi: 10.1007/s00125-024-06095-7.
No abstract available

Publication types

  • Published Erratum